Drug development - insights
1.3K views | +0 today
Follow
Drug development - insights
Look at what is happening in drug development world - sharing the insights
Your new post is loading...
Your new post is loading...
Scooped by James A Smith MCIM
Scoop.it!

Who's The Best In Drug Research? 22 Companies Ranked

Who's The Best In Drug Research? 22 Companies Ranked | Drug development - insights | Scoop.it
Billionaire hedge fund manager Bill Ackman is fundamentally wrong in the arguments that he is making in his efforts to force Botox-maker Allergan to sell itself to Valeant Pharmceuticals. Merck and Novartis, both regarded as paragons of R&D, are actually laggards. And Pfizer and AstraZeneca, far from sad sacks driven [...]
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

AZ offloads more products in slimming drive - PMLiVE

AZ offloads more products in slimming drive - PMLiVE | Drug development - insights | Scoop.it
Will invest Moventig, Plendil and Imdur proceeds in its R&D pipeline
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

The Ultimate Review on how Biotech Changed Cancer

The Ultimate Review on how Biotech Changed Cancer | Drug development - insights | Scoop.it
Cancer: Reviewing different Biotech Oncology treatments, to include Monoclonal antibodies, Immuno-oncology, Gene Therapy, Cell Therapy and of course, CAR-T.
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

Third Quarter – A Reality Check: The Cost of Innovative Drugs Moves into Politicos’ Crosshairs, but Biotech Will Recover | Life Sciences Connect

Third Quarter – A Reality Check: The Cost of Innovative Drugs Moves into Politicos’ Crosshairs, but Biotech Will Recover | Life Sciences Connect | Drug development - insights | Scoop.it
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

Four key insights from ASCO 2015 – Novartis Pharmaceuticals

Four key insights from ASCO 2015 – Novartis Pharmaceuticals | Drug development - insights | Scoop.it
Our team shares what they found most interesting at an annual meeting of oncologists.
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

Could umbilical cords yield more stem cells for life-saving transplants? | Novartis

Umbilical cords are a potentially life-saving source of blood stem cells for people with leukemia and other diseases. But there aren’t enough cells to meet demand. Now an experimental treatment offers hope for a solution.
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

Refining UK market access | Pharmafile

Refining UK market access | Pharmafile | Drug development - insights | Scoop.it
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

Q&A: Big Pharma or CRO – where’s better to work?

Q&A: Big Pharma or CRO – where’s better to work? | Drug development - insights | Scoop.it
We interview Dr Andrea Sisneros, Senior Regulatory Consultant, about her experiences of working both in Pharma and Clinical Research Organisations.
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

FDA clarifies the line between wellness and regulated medical devices | mobihealthnews

FDA clarifies the line between wellness and regulated medical devices | mobihealthnews | Drug development - insights | Scoop.it
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

Developments in Immuno-Oncology

Developments in Immuno-Oncology | Drug development - insights | Scoop.it
This article will take a look at some of the most advanced of the current immuno-oncology combinations in development.
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

Using Digital Insights during Prelaunch in the Pharmaceutical Industry — Medium

Using Digital Insights during Prelaunch in the Pharmaceutical Industry — Medium | Drug development - insights | Scoop.it
Getting a competitive edge planning for product launch through listening to 1000s of digital voices & footprints
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

The 20 best science images of the year? - BBC News

The 20 best science images of the year? - BBC News | Drug development - insights | Scoop.it
From multicoloured scans of the human body, to vivid photos of creatures up close - the finalists of the annual Wellcome Image Awards.
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

FDA clears Imbruvica as chemo alternative for first-line CLL - PMLiVE

FDA clears Imbruvica as chemo alternative for first-line CLL - PMLiVE | Drug development - insights | Scoop.it
Johnson & Johnson/AbbVie's first-in-class drug now approved for all CLL patients
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

Threshold of toxicological concern concept and its use in agrochemical and chemical risk assessment

Threshold of toxicological concern concept and its use in agrochemical and chemical risk assessment | Drug development - insights | Scoop.it
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

FDA approves first 3D-printed drug

FDA approves first 3D-printed drug | Drug development - insights | Scoop.it
A private Pennsylvania company says it has made the first 3D-printed drug to be approved by the US FDA.
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

6 New FDA Orphan Drug Designations: Week of 06/01/15

6 New FDA Orphan Drug Designations: Week of 06/01/15 | Drug development - insights | Scoop.it
            The chart below identifies 6 new FDA Products Receiving Orphan Designation for the week of 06/01 – 06/05/15 as of 06/07/15 in ascending “Orphan Drug Designation...
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

Is this the end of the science geek?

Is this the end of the science geek? | Drug development - insights | Scoop.it
Scientific experts in silos are no longer meeting the needs of the industry, so what skills and expertise does a life science professional need to possess?
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

10 Largest Companies by Market Cap in Pharmaceuticals (GSK, JNJ, LLY, MRK, PFE)

10 Largest Companies by Market Cap in Pharmaceuticals (GSK, JNJ, LLY, MRK, PFE) | Drug development - insights | Scoop.it
The 10 largest pharmaceuticals by market cap are packed with great dividends and substantial cash flow, but not all are slam-dunk investments. - Sean Williams - Health Care
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

Thomson Reuters Names Most Promising Drugs of 2015

Annual forecast finds significant increase in the number of blockbusters set to enter this year’s market
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

The coming revolution in much cheaper life-saving drugs

The coming revolution in much cheaper life-saving drugs | Drug development - insights | Scoop.it
The government is close to approving the first in a new class of drugs, cheaper copycat versions of medicines that treat everything from arthritis to cancer.
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

Man Saves Wife's Sight by 3D Printing Her Tumor

Man Saves Wife's Sight by 3D Printing Her Tumor | Drug development - insights | Scoop.it
When his wife was misdiagnosed, Michael Balzer used 3D printing and imaging to get her well
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

Rare Diseases and Biomarkers - Challenges and Opportunities

Rare Diseases and Biomarkers - Challenges and Opportunities | Drug development - insights | Scoop.it
In spite of being termed rare, there are an estimated 7,000 of these disorders and they affect around 30 million people just in the US.
more...
No comment yet.
Scooped by James A Smith MCIM
Scoop.it!

23andMe Turns Spit Into Dollars in Deal With Pfizer

23andMe Turns Spit Into Dollars in Deal With Pfizer | Drug development - insights | Scoop.it
23andMe Inc., the genetic-testing startup backed by Google Inc., is sharing DNA data on about 650,000 individuals with Pfizer Inc., to help find new targets to treat disease and to design clinical trials.
more...
No comment yet.